Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2019 | 572 | 0.55 | Why? |
| Contrast Media | 1 | 2018 | 1011 | 0.45 | Why? |
| Aftercare | 1 | 2021 | 1637 | 0.43 | Why? |
| Academic Medical Centers | 1 | 2021 | 3088 | 0.37 | Why? |
| Seasons | 1 | 2019 | 4071 | 0.31 | Why? |
| Patient Discharge | 1 | 2021 | 5696 | 0.28 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2019 | 2984 | 0.27 | Why? |
| Length of Stay | 2 | 2021 | 11042 | 0.26 | Why? |
| Spain | 6 | 2021 | 15545 | 0.26 | Why? |
| Hidradenitis Suppurativa | 2 | 2019 | 309 | 0.26 | Why? |
| Influenza Vaccines | 1 | 2019 | 2941 | 0.24 | Why? |
| Health Personnel | 4 | 2021 | 29646 | 0.22 | Why? |
| Lung Neoplasms | 1 | 2018 | 3228 | 0.21 | Why? |
| Antitreponemal Agents | 1 | 2018 | 1 | 0.20 | Why? |
| Clindamycin | 1 | 2019 | 59 | 0.19 | Why? |
| Iopamidol | 1 | 2018 | 19 | 0.19 | Why? |
| Cross Infection | 1 | 2021 | 8675 | 0.19 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 9706 | 0.18 | Why? |
| Radiography, Abdominal | 1 | 2018 | 88 | 0.17 | Why? |
| Rifampin | 1 | 2019 | 276 | 0.16 | Why? |
| tau Proteins | 1 | 2017 | 162 | 0.16 | Why? |
| Artifacts | 1 | 2018 | 250 | 0.15 | Why? |
| Amyloid beta-Peptides | 1 | 2017 | 185 | 0.15 | Why? |
| Cross-Over Studies | 1 | 2018 | 867 | 0.14 | Why? |
| Occupations | 1 | 2020 | 733 | 0.14 | Why? |
| Syphilis | 1 | 2018 | 318 | 0.14 | Why? |
| Influenza, Human | 1 | 2019 | 10779 | 0.13 | Why? |
| Carotid Artery Diseases | 1 | 2017 | 251 | 0.13 | Why? |
| Case-Control Studies | 4 | 2021 | 17671 | 0.13 | Why? |
| Radiation Dosage | 1 | 2018 | 585 | 0.13 | Why? |
| Program Evaluation | 1 | 2021 | 1929 | 0.12 | Why? |
| Sentinel Surveillance | 1 | 2019 | 1093 | 0.11 | Why? |
| Patient Readmission | 1 | 2021 | 1543 | 0.11 | Why? |
| Logistic Models | 3 | 2021 | 9089 | 0.11 | Why? |
| Feasibility Studies | 1 | 2021 | 3467 | 0.11 | Why? |
| Radioimmunoassay | 1 | 2010 | 25 | 0.11 | Why? |
| Tomography, X-Ray Computed | 1 | 2018 | 25144 | 0.11 | Why? |
| Zinc | 1 | 2018 | 817 | 0.11 | Why? |
| Odds Ratio | 2 | 2021 | 5861 | 0.11 | Why? |
| Middle Aged | 13 | 2021 | 270681 | 0.10 | Why? |
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2018 | 869 | 0.10 | Why? |
| Vaccination Coverage | 1 | 2019 | 1249 | 0.10 | Why? |
| Hypogonadism | 1 | 2010 | 196 | 0.09 | Why? |
| Medication Adherence | 1 | 2019 | 1270 | 0.09 | Why? |
| Male | 15 | 2021 | 367725 | 0.09 | Why? |
| Adult | 11 | 2021 | 244371 | 0.09 | Why? |
| Personnel, Hospital | 1 | 2021 | 2273 | 0.09 | Why? |
| Alzheimer Disease | 1 | 2017 | 1020 | 0.08 | Why? |
| Public Health Surveillance | 1 | 2020 | 3129 | 0.08 | Why? |
| Anti-HIV Agents | 2 | 2017 | 2209 | 0.08 | Why? |
| Age Factors | 4 | 2021 | 21039 | 0.08 | Why? |
| Female | 13 | 2021 | 380317 | 0.08 | Why? |
| Peptide Fragments | 1 | 2017 | 2075 | 0.08 | Why? |
| Surgical Wound Infection | 1 | 2011 | 501 | 0.08 | Why? |
| Aged | 8 | 2021 | 215776 | 0.07 | Why? |
| Cognitive Dysfunction | 1 | 2017 | 1389 | 0.07 | Why? |
| Treatment Outcome | 3 | 2021 | 51732 | 0.07 | Why? |
| Testosterone | 1 | 2010 | 596 | 0.07 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.06 | Why? |
| Gastrointestinal Tract | 1 | 2011 | 1113 | 0.06 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.06 | Why? |
| Humans | 18 | 2021 | 930598 | 0.06 | Why? |
| Tertiary Care Centers | 1 | 2020 | 8248 | 0.06 | Why? |
| Radiography, Thoracic | 1 | 2018 | 5486 | 0.05 | Why? |
| Aged, 80 and over | 4 | 2019 | 88759 | 0.05 | Why? |
| Time Factors | 2 | 2021 | 31397 | 0.05 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.05 | Why? |
| Anti-Bacterial Agents | 2 | 2019 | 10083 | 0.05 | Why? |
| Arsphenamine | 1 | 2018 | 1 | 0.05 | Why? |
| Mercury Compounds | 1 | 2018 | 10 | 0.05 | Why? |
| History, 15th Century | 1 | 2018 | 73 | 0.05 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.05 | Why? |
| Bismuth | 1 | 2018 | 56 | 0.05 | Why? |
| Masks | 1 | 2021 | 8528 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.05 | Why? |
| HIV Infections | 2 | 2017 | 11620 | 0.04 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.04 | Why? |
| National Institute on Aging (U.S.) | 1 | 2017 | 9 | 0.04 | Why? |
| DNA, Ribosomal | 1 | 2017 | 112 | 0.04 | Why? |
| Severity of Illness Index | 3 | 2020 | 48226 | 0.04 | Why? |
| Risk Factors | 4 | 2021 | 71621 | 0.04 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.04 | Why? |
| Retrospective Studies | 4 | 2021 | 105322 | 0.04 | Why? |
| Biomarkers | 2 | 2017 | 23361 | 0.04 | Why? |
| Carotid Intima-Media Thickness | 1 | 2017 | 179 | 0.04 | Why? |
| Prospective Studies | 2 | 2018 | 43301 | 0.04 | Why? |
| Infant | 1 | 2019 | 30274 | 0.04 | Why? |
| Infusions, Intravenous | 1 | 2020 | 1224 | 0.04 | Why? |
| Drug Therapy, Combination | 2 | 2020 | 7268 | 0.04 | Why? |
| Child, Preschool | 1 | 2019 | 36283 | 0.04 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.04 | Why? |
| Lipopolysaccharide Receptors | 1 | 2017 | 357 | 0.03 | Why? |
| Respiratory Function Tests | 1 | 2020 | 1755 | 0.03 | Why? |
| Young Adult | 3 | 2019 | 93724 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2018 | 1444 | 0.03 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.03 | Why? |
| History, 20th Century | 1 | 2018 | 1282 | 0.03 | Why? |
| Child | 2 | 2019 | 70012 | 0.03 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.03 | Why? |
| Administration, Oral | 1 | 2019 | 2340 | 0.03 | Why? |
| Sex Hormone-Binding Globulin | 1 | 2010 | 57 | 0.03 | Why? |
| Follicle Stimulating Hormone | 1 | 2010 | 73 | 0.03 | Why? |
| Luteinizing Hormone | 1 | 2010 | 91 | 0.03 | Why? |
| Interleukin-6 | 2 | 2020 | 7522 | 0.03 | Why? |
| Prolactin | 1 | 2010 | 68 | 0.03 | Why? |
| Adolescent | 2 | 2019 | 86841 | 0.03 | Why? |
| Follow-Up Studies | 2 | 2020 | 17020 | 0.03 | Why? |
| Reference Values | 1 | 2010 | 795 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Prognosis | 2 | 2021 | 32490 | 0.02 | Why? |
| Survival Analysis | 1 | 2020 | 7592 | 0.02 | Why? |
| Hospital Mortality | 2 | 2021 | 22087 | 0.02 | Why? |
| Survival Rate | 1 | 2021 | 9206 | 0.02 | Why? |
| Smoking | 1 | 2019 | 3358 | 0.02 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2010 | 952 | 0.02 | Why? |
| Europe | 1 | 2021 | 12702 | 0.02 | Why? |
| Body Mass Index | 1 | 2017 | 4306 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Time-to-Treatment | 1 | 2020 | 5883 | 0.02 | Why? |
| Elective Surgical Procedures | 1 | 2021 | 5338 | 0.02 | Why? |
| Mass Screening | 1 | 2021 | 8005 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.01 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.01 | Why? |
| Cohort Studies | 1 | 2021 | 36005 | 0.01 | Why? |
| Viral Load | 1 | 2017 | 15850 | 0.01 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.01 | Why? |
| Pandemics | 2 | 2020 | 389249 | 0.01 | Why? |
| Predictive Value of Tests | 1 | 2010 | 9537 | 0.01 | Why? |
| Delivery of Health Care | 1 | 2021 | 15909 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| United States | 1 | 2017 | 46150 | 0.01 | Why? |
Sánchez-Payá's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(136)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(91)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_